Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy for Primary CNS Tumors
NCT04939597Phase 3Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- May 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Carcinoma of the central nervous system comparing Arm I (memantine hydrochloride) with Arm II (placebo) (2 arms). Primary endpoint: Mean slope of the Cogstate composite Z score at 12 months. Started May 2022; status: active, not recruiting.
02
Drugs
memantine
03
Conditions
Carcinoma of the central nervous system
Beyond the preview
Go deeper on NCT04939597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939597.